ORIC’s Redwood-1 trial for enozertinib will test drug against osimertinib or afatinib
ORIC Pharmaceuticals plans a Phase 3 trial comparing enozertinib to osimertinib or afatinib in 1L EGFR atypical NSCLC, as FDA records confirm two prior osimertinib approvals.
FDA, SEC filing (3)